Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128068 | 1.00 | MAPT (0.36) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7124862 | 0.93 | CHRNA1 (0.36) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7124857 | 0.93 | CHRNA1 (0.36) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL9026312 | 0.88 | MAPT (0.35) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL9025805 | 0.81 | CHRNA1 (0.35) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7122960 | 0.77 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2ALDH1A1CHRNA1CHRNA3 | |
| SCHEMBL7122937 | 0.74 | ALDH1A1 (0.40) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7122932 | 0.74 | ALDH1A1 (0.40) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7127980 | 0.72 | ALDH1A1 (0.38) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7240778 | 0.72 | ALDH1A1 (0.38) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664248-B2 | Well tolerated by animals, fish and plants | SYNGENTA INVESTMENT CORP. | 2003-12-16 | — | — | US | claimed |
| US-20030166635-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | MAIENFISCH PETER (CH) | 2003-09-04 | — | — | US | claimed |
| US-6506743-B2 | Especially for controlling insects. | SYNGENTA INVESTMENT CORPORATION | 2003-01-14 | — | — | US | claimed |
| US-20020068733-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | MAIENFISCH PETER (CH) | 2002-06-06 | — | — | US | claimed |
| EP-0693066-B1 | 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-05-16 | — | — | EP | claimed |
| EP-0693066-A1 | NOVEL 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | Novartis AG (CH) | 1996-01-24 | — | — | EP | claimed |
| WO-1994024124-A1 | NOVEL 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | claimed |
| US-6664248-B2 | Well tolerated by animals, fish and plants | SYNGENTA INVESTMENT CORP. | 2003-12-16 | — | — | US | disclosed |
| US-20030166635-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | MAIENFISCH PETER (CH) | 2003-09-04 | — | — | US | disclosed |
| US-6506743-B2 | Especially for controlling insects. | SYNGENTA INVESTMENT CORPORATION | 2003-01-14 | — | — | US | disclosed |
| US-20020068733-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | MAIENFISCH PETER (CH) | 2002-06-06 | — | — | US | disclosed |
| US-6353001-B1 | PESTICIDES, INSECTICIDES, APHIDICIDES AND LARVICIDES | SYNGENTA INVESTMENT CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-0693066-B1 | 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-05-16 | — | — | EP | disclosed |
| US-6048824-A | 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | NOVARTIS CORPORATION (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0693066-A1 | NOVEL 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | Novartis AG (CH) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994024124-A1 | NOVEL 2-NITROMETHYLIDENE/2-CYANIMINO/2-NITRO-IMINO-PYRROLIDINES AND PIPERIDINES, INTERMEDIATES, AND THEIR USE AS PESTICIDES | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068733-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | HCN1, HCN2, CNTN1 | MAPT 1746/4885SMN1; SMN2 981/4885LMNA 1221/4885 |
| US-20030166635-A1 | Novel 2-nitromethylidene/2-cyanimino/2-nitro-imino-pyrrolidines and piperidines, intermediates, and their use as pesticides | HCN1, HCN2, CNTN1 | MAPT 1212/4885SMN1; SMN2 777/4885LMNA 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.